Quarterly ResultMay 8, 2026, 07:01 AM
ANI Pharma Q1 Revenue +20.5% to $237.5M; Raises 2026 Guidance; $100M Buyback
AI Summary
ANI Pharmaceuticals reported strong first-quarter 2026 financial results, with net revenues increasing 20.5% year-over-year to $237.5 million and adjusted non-GAAP EBITDA growing 24.1% to $63.0 million. The company saw significant growth in its Rare Disease segment, particularly Cortrophin Gel, and continued momentum in its Generics business. Based on this performance, ANI Pharmaceuticals raised its full-year 2026 financial guidance for total net revenue and adjusted non-GAAP EBITDA. Additionally, the Board of Directors authorized a new $100 million share repurchase program.
Key Highlights
- Q1 2026 net revenues increased 20.5% year-over-year to $237.5 million.
- Cortrophin Gel net revenues rose 42.1% to $75.1 million in Q1 2026.
- ILUVIEN net revenues increased 19.5% to $19.3 million in Q1 2026.
- Generics net revenues grew 6.8% to $105.4 million in Q1 2026.
- Q1 2026 GAAP net income available to common shareholders was $29.5 million, or $1.28 per diluted share.
- Adjusted non-GAAP EBITDA increased 24.1% to $63.0 million in Q1 2026.
- Raised 2026 total net revenue guidance to $1,080M-$1,140M and adjusted non-GAAP EBITDA to $285M-$300M.
- Board authorized a new $100 million share repurchase program through May 2029.